Fluxergy Partners with NIAID to Advance Multimodal POC Diagnostics
Fluxergy is collaborating with NIAID to enhance molecular testing and sample preparation on its innovative platform.
Read MorePosted by Andy Lundin | Nov 19, 2024 | Point-of-Care, Sample Storage & Management |
Fluxergy is collaborating with NIAID to enhance molecular testing and sample preparation on its innovative platform.
Read MorePosted by Chris Wolski | Nov 13, 2024 | Diagnostic Technologies |
For the second year in a row, industry experts predict automation and AI as top clinical laboratory trends in 2025.
Read MorePosted by Andy Lundin | Nov 13, 2024 | Mass Spectrometry Reagents & Test Kits, Point-of-Care |
This collaboration aims to advance a smartphone-based hemoglobin test for accessible diagnostics of anemia and other health conditions.
Read MorePosted by Andy Lundin | Nov 12, 2024 | Molecular Diagnostics, Prostate |
A genetic variant in the PSA gene may help improve prostate cancer diagnostics by distinguishing between aggressive and non-aggressive types.
Read MorePosted by Andy Lundin | Nov 4, 2024 | Sexually Transmitted Diseases |
WHO has granted Cepheid’s Xpert Mpox test Emergency Use Listing, enabling rapid, point-of-care mpox detection to support outbreak management.
Read More